Erratum: Activation of AMP-activated protein kinase and extracelluar signal-regulated kinase mediates CB-PIC-induced apoptosis in hypoxic SW620 colorectal cancer sells (Evidence-Based Complementary and Alternative Medicine (2013) 2013 (974313) DOI: 10.1155/2013/974313);Activation of AMP-activated protein kinase α and extracelluar signal-regulated kinase mediates CB-PIC-induced apoptosis in hypoxic SW620 colorectal cancer cells

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Cho, Sung Yun ^a   Lee, Hyo Jeong ^a   Lee, Hyo Jung ^a   Jung, Deok Beom ^a   Kim, Hyunseok ^a   Sohn, Eun Jung ^a   Kim, Bonglee ^a   Jung, Ji Hoon ^a   Kwon, Byoung Mog ^b   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [(2 (3 OXOPOP 1 ENYL)PHENOXY)METHYL]PYRIDINIUM MALONIC ACID; AMP ACTIVATED PROTEIN KINASE ALPHA; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CINNAMALDEHYDE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84876578690     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2020/6289392     Document Type: Erratum

References (37)

1. Harris A. L., Hypoxia-a key regulatory factor in tumour growth. Nature Reviews Cancer 2002 2 1 38 47 2-s2.0-0036359548 (Pubitemid 37328806)
2. Yee Koh M., Spivak-Kroizman T. R., Powis G., HIF-1 regulation: not so easy come, easy go. Trends in Biochemical Sciences 2008 33 11 526 534 2-s2.0-54249164450 10.1016/j.tibs.2008.08.002
3. Shackelford D. B., Shaw R. J., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Reviews Cancer 2009 9 8 563 575 2-s2.0-67749111502 10.1038/nrc2676
4. Hardie D. G., Hawley S. A., Scott J. W., AMP-activated protein kinase-development of the energy sensor concept. The Journal of Physiology 2006 574, part 1 7 15 2-s2.0-33745225026 10.1113/jphysiol.2006.108944 (Pubitemid 43905792)
5. Misra P., AMP activated protein kinase: a next generation target for total metabolic control. Expert Opinion on Therapeutic Targets 2008 12 1 91 100 2-s2.0-39049105534 10.1517/14728222.12.1.91 (Pubitemid 351247165)
6. Fruman D. A., Edinger A. L., Cancer therapy: staying current with AMPK. The Biochemical Journal 2008 412 2 e3 e5 2-s2.0-46249121405 10.1042/BJ20080823
7. Hsu Y. C., Meng X., Ou L., Ip M. M., Activation of the AMP-activated protein kinase-p38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53-mutant mouse mammary tumor cells. Cellular Signalling 2010 22 4 590 599 2-s2.0-74449087616 10.1016/j.cellsig.2009.11.011
8. Huang X., Wullschleger S., Shpiro M., McGuire V. A., Sakamoto K., Woods Y. L., McBurnie W., Fleming S., Alessi D. R., Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochemical Journal 2008 412 2 211 221 2-s2.0-44449103256 10.1042/BJ20080557 (Pubitemid 351758227)
9. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., Yang Q., Bennett C., Harada Y., Stankunas K., Wang C. Y., He X., MacDougald O. A., You M., Williams B. O., Guan K. L., TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006 126 5 955 968 2-s2.0-33748153690 10.1016/j.cell.2006.06.055 (Pubitemid 44310775)
10. Guertin D. A., Sabatini D. M., Defining the role of mTOR in cancer. Cancer Cell 2007 12 1 9 22 2-s2.0-34347220473 10.1016/j.ccr.2007.05.008 (Pubitemid 47001784)
11. Ben Sahra I., Marchand-Brustel Y. L., Tanti J. F., Bost F., Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Molecular Cancer Therapeutics 2010 9 5 1092 1099 2-s2.0-77952116629 10.1158/1535-7163.MCT-09- 1186
12. Paraskevas S., Aikin R., Maysinger D., Lakey J. R. T., Cavanagh T. J., Hering B., Wang R., Rosenberg L., Activation and expression of ERK, JNK, and p38 MAP-kinases in isolated islets of Langerhans: implications for cultured islet survival. FEBS Letters 1999 455 3 203 208 2-s2.0-0032815458 10.1016/S0014- 5793(99)00882-0 (Pubitemid 29333036)
13. Mebratu Y., Tesfaigzi Y., How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 2009 8 8 1168 1175 2-s2.0-65949119310
14. Roberts P. J., Der C. J., Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007 26 22 3291 3310 2-s2.0-34248591612 10.1038/sj.onc.1210422 (Pubitemid 46763022)
15. Chew E. H., Nagle A. A., Zhang Y., Scarmagnani S., Palaniappan P., Bradshaw T. D., Holmgren A., Westwell A. D., Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radical Biology and Medicine 2010 48 1 98 111 2-s2.0-74149084512 10.1016/j.freeradbiomed.2009.10.028
16. Jeong H. W., Han D. C., Son K. H., Han M. Y., Lim J. S., Ha J. H., Lee C. W., Kim H. M., Kim H. C., Kwon B. M., Antitumor effect of the cinnamaldehyde derivative CB403 through the arrest of cell cycle progression in the G2/M phase. Biochemical Pharmacology 2003 65 8 1343 1350 2-s2.0-0037446268 10.1016/S0006-2952(03)00038-8 (Pubitemid 36407785)
17. Huang B., Yuan H. D., Kim D. Y., Quan H. Y., Chung S. H., Cinnamaldehyde prevents adipocyte differentiation and adipogenesis via regulation of peroxisome proliferator-activated receptor- γ (PPAR γ) and AMP-activated protein kinase (AMPK) pathways. Journal of Agricultural and Food Chemistry 2011 59 8 3666 3673 2-s2.0-79955025463 10.1021/jf104814t
18. Zhang Z. L., Zou W. G., Luo C. X., Li B. H., Wang J. H., Sun L. Y., Qian Q. J., Liu X. Y., An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Research 2003 13 6 481 489 2-s2.0-1842864085 10.1038/sj.cr.7290191 (Pubitemid 43231842)
19. Powis G., Welsh S. J., Koh M. Y., The hypoxic inducible stress response as a target for cancer drug discovery. Seminars in Oncology 2006 33 4 486 497 2-s2.0-33746564193 10.1053/j.seminoncol.2006.04.011 (Pubitemid 44142742)
20. Cipro S., Hřebačková J., Hraběta J., Valproic acid overcomes hypoxia-induced resistance to apoptosis. Oncology Reports 2012 27 4 1219 1226
21. Fay J. R., Steele V., Crowell J. A., Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prevention Research 2009 2 4 301 309 2-s2.0-67549131188 10.1158/1940-6207.CAPR-08-0166
22. Tang D. M., Wu D., Hirao A., Lahti J. M., Liu L., Mazza B., Kidd V. J., Mak T. W., Ingram A. J., ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. The Journal of Biological Chemistry 2002 277 15 12710 12717 2-s2.0-0037066686 10.1074/jbc.M111598200 (Pubitemid 34952631)
23. Jalving M., Gietema J. A., Lefrandt J. D., Jong S. D., Reyners A. K. L., Gans R. O. B., Vries E. G. E. D., Metformin: taking away the candy for cancer? European Journal of Cancer 2010 46 13 2369 2380 2-s2.0-77955923866 10.1016/j.ejca.2010.06.012
24. Evans J. M. M., Donnelly L. A., Emslie-Smith A. M., Alessi D. R., Morris A. D., Metformin and reduced risk of cancer in diabetic patients. British Medical Journal 2005 330 7503 1304 1305 2-s2.0-20444461067 10.1136/bmj.38415. 708634.F7 (Pubitemid 40813563)
25. Smith T. G., Robbins P. A., Ratcliffe P. J., The human side of hypoxia-inducible factor. British Journal of Haematology 2008 141 3 325 334 2-s2.0-42049115510 10.1111/j.1365-2141.2008.07029.x (Pubitemid 351521147)
26. Semenza G. L., Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004 5 5 405 406 2-s2.0-2342661143 10.1016/S1535-6108(04)00118-7 (Pubitemid 38610240)
27. Voss M. J., Niggemann B., Zanker K. S., Tumour reactions to hypoxia. Current Molecular Medicine 2010 10 4 381 386 10.2174/156652410791317020
28. Wang W., Guan K. L., AMP-activated protein kinase and cancer. Acta Physiologica 2009 196 1 55 63 2-s2.0-63849104290 10.1111/j.1748-1716.2009.01980. x
29. Lu Z., Xu S., ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006 58 11 621 631 2-s2.0-33750616041 10.1080/15216540600957438 (Pubitemid 44691463)
30. Sacks D. B., The role of scaffold proteins in MEK/ERK signalling. Biochemical Society Transactions 2006 34, part 5 833 836 2-s2.0-33751294581 10.1042/BST0340833 (Pubitemid 44796432)
31. Zhuang S., Schnellmann R. G., A death-promoting role for extracellular signal-regulated kinase. Journal of Pharmacology and Experimental Therapeutics 2006 319 3 991 997 2-s2.0-33751190327 10.1124/jpet.106.107367
32. Sinha D., Bannergee S., Schwartz J. H., Lieberthal W., Levine J. S., Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis. The Journal of Biological Chemistry 2004 279 12 10962 10972 2-s2.0-1642565343 10.1074/jbc.M312048200 (Pubitemid 38401587)
33. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 2-s2.0-0142166332 (Pubitemid 37328811)
34. Inoki K., Kim J., Guan K. L., AMPK and mTOR in cellular energy homeostasis and drug targets. Annual Review of Pharmacology and Toxicology 2012 52 381 400 10.1146/annurev-pharmtox-010611-134537
35. Kopelovich L., Fay J. R., Sigman C. C., Crowell J. A., The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiology Biomarkers and Prevention 2007 16 7 1330 1340 2-s2.0-34447530619 10.1158/1055-9965.EPI-07-0045 (Pubitemid 47076862)
36. DeClerck K., Elble R. C., The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Frontiers in Bioscience 2010 15 1 213 225 2-s2.0-77951228314 10.2741/3616
37. Doublier S., Belisario D. C., Polimeni M., HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 2012 12, article 4